WJ-39

• Description :

  WJ-39 is an orally active aldose reductase (AR) inhibitor. WJ-39 improves tubular damage in diabetic nephropathy rats by activating PINK1/Parkin signaling, promoting mitophagy, and attenuating apoptosis[1].

• UNSPSC :

  12352005

• Target :

  Aldose Reductase; Apoptosis; Mitochondrial Metabolism; Mitophagy

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Autophagy; Metabolic Enzyme/Protease

• Applications :

  Metabolism-sugar/lipid metabolism

• Field of Research :

  Metabolic Disease

• Assay Protocol :

  https://www.medchemexpress.com/wj-39.html

• Concentration :

  10mM

• Purity :

  99.60

• Solubility :

  DMSO : ≥ 350 mg/mL

• Smiles :

  COC1=CC=C(N(CC(O[K])=O)C=C(CC2=CC=CC(Cl)=C2Cl)C3=O)C3=C1

• Molecular Formula :

  C19H14Cl2KNO4

• Molecular Weight :

  430.32

• References & Citations :

  [1]Yang L, et al. An aldose reductase inhibitor, WJ-39, ameliorates renal tubular injury in diabetic nephropathy by activating PINK1/Parkin signaling. Eur J Pharmacol. 2024 Mar 15;967:176376.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, protect from light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [3009908-95-3]